Structure via PubChem · Public domain (PubChem)
レボチロキシン
Sign in to saveAlso known as levothyroxine sodium, Levothyroxin, 4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodo-L-phenylalanine, LT4, 3,3',5,5'-Tetraiodo-L-thyronine, Levothyroxine, O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodo-L-tyrosine, T4
Levothyroxine, also known as -thyroxine, is a synthetic form of the thyroid hormone thyroxine (T4). It is used to treat thyroid hormone deficiency (hypothyroidism), including a severe form known as myxedema coma. It may also be used to treat and prevent certain types of thyroid tumors. It is not indicated for weight loss. Levothyroxine is taken orally (by mouth) or given by intravenous injection. Levothyroxine has a half-life of 7.5 days when taken daily, so about six weeks is required for it to reach a steady level in the blood.
Key facts
- Drug.image
- Levothyroxine 200.svg
- Drug.image_class
- skin-invert-image
- Drug.image2
- Levothyroxine-from-xtal-3D-bs-17.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Synthroid, Levoxyl, others
- Drug.MedlinePlus
- a682461
- Drug.DailyMedID
- Levothyroxine
- Drug.pregnancy_AU
- A
- Drug.routes_of_administration
- By mouth, intravenous
- Drug.ATC_prefix
- H03
- Drug.ATC_suffix
- AA01
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx only
- Drug.bioavailability
- 40-80%
- Drug.metabolism
- Mainly in the liver, kidneys, brain, and muscles
- Drug.elimination_half life
- ca. 7 days (in hyperthyroidism 3–4 days, in hypothyroidism 9–10 days)
- Drug.excretion
- Feces and urine
via Wikipedia infobox
Chemical data
- Formula
- C15H11I4NO4
- Molecular weight
- 776.87 g/mol
- IUPAC name
- (2S)-2-azaniumyl-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate
- SMILES
- C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)[O-])[NH3+]
- InChIKey
- XUIIKFGFIJCVMT-LBPRGKRZSA-N
- XLogP
- 3
- Polar surface area
- 97.2 Ų
- H-bond donors
- 2
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 1982
- Admin. routes
- oral, parenteral
- Indications
- diabetes mellitus, pregnancy, Graves disease, hypothyroidism
via ChEMBL · EBI
Wikidata facts
- Subclass of
- thyroxine
- Mass
- 776.686699832
- Has use
- medication
Show 14 more facts
- medical condition treated
- goiter
- isomeric SMILES
- C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N
- canonical SMILES
- C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)O)N
- found in taxon
- Homo sapiens
- location of creation
- Bourgoin-Jallieu
- MCN code
- 3004.39.81
- chemical formula
- C₁₅H₁₁I₄NO₄
- melting point
- 232
- solubility
- 105
- half-life
- 1
- Commons category
- Levothyroxine
- subject has role
- primary metabolite
- significant drug interaction
- phenytoin
- legal status (medicine)
- boxed warning
Sources (8)
via Wikidata · CC0
Article · 日本語
レボチロキシン（Levothyroxine）またはL-チロキシンは、甲状腺ホルモンの1つであり、T4との略称を持つ。医薬品としては甲状腺機能低下症の治療に用いられたり、甲状腺癌の予防に用いられる事もある。不斉炭素を1つ持つ化合物であり、自然に存在するチロキシンと同じくL-型である。商品名チラーヂン。対掌体であるD-チロキシンは高コレステロール血症治療への応用が考えられた事があるが、心毒性のために開発中止となった。 WHO必須医薬品モデル・リストに収載されている。
Abstract from DBpedia / Wikipedia · CC BY-SA